Granules Life Sciences Private Limited, a active private limited company, was established on 18 November 2020 in Serilingampally, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24290TG2020PTC146042. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹450.00 Cr and a paid-up capital of ₹450.00 Cr.
It upholds a compliant status. Employing 23 professional, Its leadership includes Rajiv Pritidas Kakodkar (Director), Chigurupati Krishna Prasad (Director), Umadevi Chigurupati (Director). Past directors included Rajiv Pritidas Kakodkar, Umadevi Chigurupati, Priyanka Chigurupati. It holds ₹400.00 Cr open charges and no settled loans. Its latest AGM occurred on 06 August 2025, with the balance sheet filed on 31 March 2025. It is based at 15Th Floor, Granules Tower, Botanical Garden Road, Serilingampally, Telangana, 500084.
U24290TG2020PTC146042
146042
18 November 2020
₹450.00 Cr
₹450.00 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Granules Life Sciences Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Rajiv Pritidas Kakodkar | Director | 30 Mar 2024 | Current |
| Chigurupati Krishna Prasad | Director | 18 Nov 2020 | Current |
| Umadevi Chigurupati | Director | 30 Mar 2024 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 04 Aug 2024 | Past |
| Pramod Abcsdd | Additional Director | 04 Aug 2024 | Past |
| Pramod Abcsdd | Director | 30 Mar 2024 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Granules Life Sciences Private Limited, for the financial year ended 2024, experienced significant growth in revenue, with a 71.69% increase. The company also saw a substantial fall in profitability, with a 335.2% decrease in profit. The company's net worth Soared by an impressive increase of 275.75%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2024, Granules Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹4,000,000,000.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Feb 2024 | Sbicap Trustee Company Limited | ₹400.00 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Granules Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Granules Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Granules Life Sciences's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Granules Life Sciences Private Limited last Annual general meeting of members was held on 06 Aug 2025 as per latest MCA records. was recorded as a recent event.
The activity Chaitanya Tummala was appointed as a Company Secretary was appointed as a Company Secretary on 03 Apr 2025 & has been associated with this company since 8 months . was completed.
Progress on Granules Life Sciences Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Hyderabad. was documented.
Mukesh Mahavirchand Surana was appointed as a CFO was appointed as a CFO on 19 Apr 2024 & has been associated with this company since 1 year 7 months . was recorded as a recent event.
The activity Rajiv Pritidas Kakodkar was appointed as a Director was appointed as a Director on 30 Mar 2024 & has been associated with this company since 1 year 8 months . was completed.
Progress on Umadevi Chigurupati was appointed as a Director was appointed as a Director on 30 Mar 2024 & has been associated with this company since 1 year 8 months . was documented.
Granules India Q3 FY24 Results Live : Revenue increased by 0.83% YoY & profit increasedby 1.06% YoY.
Granules India's Q2 FY24 results showed a 3.37% increase in revenue but a 29.62% decrease in profit compared to last year. However, compared to the previous quarter, there was significant growth in revenue and profit. Operating income increased by 83.2% but decreased by 19.31% compared to last year. EPS for Q2 FY24 is ₹4.22, a 27.49% decrease from last year. The company has delivered good returns and has a Strong Buy recommendation from analysts. Keep up with their results on our calendar..
Granules India has received approval from the US Food & Drug Administration (USFDA) for its generic Esomeprazole Magnesium delayed-release capsules. The capsules are used for the short-term treatment of heartburn and other symptoms of gastroesophageal reflux disease. The approval is for capsules with strengths of 20 mg and 40 mg, and they are bioequivalent and therapeutically equivalent to the reference drug, Nexium..
The CIN of Granules Life Sciences Private Limited is U24290TG2020PTC146042.
Granules Life Sciences Private Limited is headquartered at 15Th Floor, Granules Tower, Botanical Garden Road, Serilingampally, Telangana, 500084.
Granules Life Sciences Private Limited was incorporated on 18 November 2020.
The current directors of Granules Life Sciences Private Limited are
The primary industry of Granules Life Sciences Private Limited is Manufacturing.
Granules Life Sciences Private Limited is unlisted.
The authorized capital of Granules Life Sciences Private Limited is ₹450.00 Cr, and the paid-up capital is ₹450.00 Cr.
The compliance status of Granules Life Sciences Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX